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Metabolic inactivation of all-tmlls retinoic acid to 
4-hydroxy retinoic acid occurs via a cytochrOine 
P-450 enzYlUe. We investigated the effects of liaro-
zole on the retinoic acid 4-hydroxylase activity of 
hUlUan epiderlUis and its ability to lUodify ill vi"o 
hUlUan skin responses to retinoic acid and all-tvatls 
retinol. Retinoic acid 4-hydroxylase activity induced 
in "i"o by 4 d treatlllent with retinoic acid (0.1%1) was 
inhibited ill ,,;tl'O by liarozole in a concentration-
dependent lUanner. Conlparable luicrolUolar concen-
trations of liarozole were extracted frolU stratun1 
corneulU-free epiderlUis treated with 3% liarozole. 
Retinoic acid levels in liarozole-treated skin in-
creased to 19 ± 5 nglg wet wt (lUean ± SEM, P < 
0.002, n = 17) at 18 h and to 6 ± 2 nglg wet wt (p = 
0.38, n = 17) at 48 h as cOlUpared to vehicle (not 
detectable). At 48 h, retinoic acid 4-hydroxylase ac-
tivity was induced 9-fold over vehicle (p < 0.03, n = 
8). At 96 h, no significant erythelUa or increased 
A lI-rral/S I'e tin o ic acid (R.A) is a phys io logic deri vative of vitmnin A (all-rralls re tino l) (RO L). which is essential fo r no rmal cellular growth and difFerentia-tio n of epithe lial tissu es in clllding skin (Gudas er ai, 1994). Human skin is also respo nsive to pharmaco-
logic le vel s of R.A applied tOpi call y (Fisher er ai, 1991; G rifl:iths el ai , 
1992) , and se veral del"lnatologic conditio ns ran ging from acne to 
p h o toa ged skin (Leyd en and Shalit;l. 1986; W eiss c/ ai, 1988; 
Weinstein ct al . 1991) have been successfull y treated with R.A. Bo th 
in c linical LI se and under con tro ll ed occlusivc patch tes t conditi ons. 
RA applica tio n to human skin is consistentl y asso ciated with an 
e rythemH respo llSe (We iss Cl (/1 , 1988; Fisher 1'1 ai, 199 1; W e in stein 
ef (/1, 199 1) , a component o f irri tation. W e ha ve recentl y demon-
stra ted in the patch test sys te m tha t topical R O L in pharm acologic 
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4-hydro"ylasc; CIt.UI'. cellular retinol bindin !-( protein . 
epiderlUal thickness was found when either retinoic 
acid (0.001%), all-tYtllls retinol (0.025%), or liarozole 
(3%) was applied individually, but when 0.001% reti-
noic acid and 3% liarozole were applied together, 
both erythelUa and increased epidermal thickness 
occurred. In contrast, 0.025% all-il'alls retinol and 3% 
liarozole together caused increased epiderlUal thick-
ness but no erythellla. These data delUonstrate that, 
at doses used here, liarozole, although an effective 
inhibitor ofretinoic acid 4-hydro"'-"ylase , cannot func-
tion alone like a retinoid ;11 ";110 , probably because of 
retinoic acid 4-hydroxylase induction. In the pres-
ence of a low dose retinoic acid or all-iYtl1fs retinol, 
however, liarozole can alnplify hUlnan skin responses 
to each retinoid in a lUanner charact eristic of the 
retinoid at a higher dose (erythelUa and hyperplasia 
with retinoic acid; no erythelUa but hyperplasia with 
all-tmlls retinol). Key words: ,'etilloidsIP-4501",etabolis",1 
;I'I'itatioll, J lIwest D evltlato/ 107:183-187, 1996 
doses can induce changes in human skin th a t arc indistinguish able 
fi'o ll1 th ose pro duced by R .A w itho ut m easurable in crease in tiss uc 
1"l...A levels o r e ry them a (Kan g cl ai, 1995) . 
Unlike its natural precursors (re tin o l and re tinalde hyd e), w hi ch 
can b e con verted to re tin yl es te rs (Blo mho tf cl al. 1992; R oss. 
1993) , R.A canno t be sto red in cell s. Pe rhaps fo r this reason , 
metabo lism of I<..A sen ' es as an impo rt'ln t h o m eo sta ti c mechanism 
to contro l tissue L~A leve ls. A m aj o r metabo lic pathwa y of in acti -
vatin g 1"l...A consists of h ydroxylati on of th e fo urth ca rbo n Htom of its 
cyclo hexenyl rin g to form 4-hydro xy-I"l...A, w hich is fur ther ox i-
dized to 4- oxo-Lli (Frolick cl ai , 1980; R o b erts cr (/ 1, 1980) . T his 
reac tio n is media ted by a cytochro m e P-450-depend ent 1110noox-
ygenase system. as evidenced b y its requirem en t for O 2 and 
N AD PH and inhibitio n b y c:l rbo n m o n o xide (R o berts ('1 al. 1979; 
Leo er ai, 1984) . In both ra t and human skin ,R.A 4-hydro xylase 
(R.A 4- 0 Hase) ac tivi ty in epidermal microsomal fractio ns is in-
du ced b y topical RA treatment (Vanden Bossche el al. 1988; D uell 
el (/1, 19(2) . T his e ffec tive ly results in f.1 ste r clearan ce of ex ogeno us 
R.A from the epidermal compartme nt. T h ere fore, if sufficien t 
inhibition o f th e h ydroxylase can be achieved with a sa fe pharma-
cologic agent. a potenti all y g reate r retin o id resp onse m ay be 
o bserved thro ugh sustain ed incl'e ases in re tino ic ac id levels. 
Liarozo le is an imidazole an alog th at inhibits ste ro id 17-Ct 
hydro xylase, an en zym e in volved in testostero ne biosynthesis 
(Bru ynsec1s cl aI, 1990). and h as been used w ith som e success to 
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t r ea t p a ti ents with ad vanced prostati c carcinoma (M a hle r ct nl , 
1989, 1993). C ompared to k e tocon azole, a relate d imidaz ol e with 
s imilar anti-androgen ac tivity, liaroz ole is better tole rated by the 
can cer p a ti e nts and has fe w e r g astroin tes tinal sidc-e ffec ts (Mahle r et 
nl , 1993 ) . In addition to its e ffect on testoste ro n e biosynthe sis , 
evide n cc exist s that liarozole al so influ e n ces RA m e ta bolism. F o r 
e x ample , o rall y admjniste r ed liarozoJe reduced the e limina tio n ra te 
of intravenously inj ected RA from rat plasma (Van Wauwe ct nl , 
1990). Furthe rmore, liaroz ole supprcssed the P-450-me diated con-
v e r sion of RA to more p o lar m e tabolites by hamste r live r micro-
somes ill lI ;tf O (Van Wauwe e( nl, 1992 ) . R ecently r eported effec-
tive n ess oforalli aroz ol e in the treatmcnt of psoriasis is presumed to 
b e rel ated to its influe n ce on RA m e ta bolism (Doc lex et nl , 1995). 
In thi s study, w e pro vide evidence that liarozole inhibits human 
skin RA 4-hydroxylase activity, that this inhibition is associa ted 
with in cre ased RA le ve ls ill 11;110, and that whe n u sed in combina-
tion with a lo w dosc RA or ROL, its retinoid-like e ffec ts ca n be 
e nhanced . 
M AT ER IALS AND METHODS 
Materials ALI-Imlls RA. all-Iralls re tino l, isocitra te . and isoc itrate deh y-
drogenase were purchased from Sigma C hemical C o ., St. Lo ui s. M O. U SA. 
IJ Hlall-trn lls RA was o btained &0 111 DuPo llt' NEN (Bosto n, MA). Liarozole 
and irtem azo le po wders we re gifts o f D r. Gee rr C all wenbcrgh at Janssc n 
Pharmace uti ca l Co. (Bee rse, Belgium). 4-H ydro xy-RA and 4-".\',,-1~ we re 
g ifts fro m Michae l R osenberge r and P. F. Sorter of H o ftin ann La-Roche 
(N utle )', NJ). 
Application of Compounds and Sldn Biopsy Procedures Solu tio ll s 
of I- I'l...A (O.OOl 'X), 0. 025%). R O L (0. 025%). liarozo le (3%). liarozolc plus 
t- I'l...A (3'10) + 0.001%). and lia rozole plus IlO L (:~% + 0.025%) we re 
prepa red ill a vehicle consistillg of 95% ethano l and propylelle glyco l (7:3; 
vo l/vo l) connlilling 0.5 mg bu ty lated h yd ro xy to luene per 1111 of so lutio n . 
T hesc solu tio ns we re used ill all the experiments ex cept in o ne to determine 
wheth er li aro zo le . added / 'x "j"", inhihi ts 1'l...A-induceel R.A- 4- hydroxylase 
ac ti vity ; fo r this experime nt, O. I 'y" R e tin - A cream was used instead. O ne 
hundred microliters of each stud y so lu ti o n (o r 0.5 g of !l.A cream) was 
appli ed ro 3 CIll X () C IlI areas on buttoc k skin o fn orl1la l hcalth y adu lts. Sites 
w ere occluded wi th Saran wrap. covered w ith a light- proo f dressin g. and 
secured w ith surgica l lapc fo r up to 4 d . Fo r treatl1le nt w ith li arozole plus 
retino id (0.U01 % I- ILA o r IU)25% R OL), the study sites we re trea ted with 
liarozolc (3%) for .3 h be fore app lication o f the combillation solu tions. 
E ry'thc lllil respo nse in test sites a fter 4 d o f occl usio n w as assesse.d w ith a 
chro mal11 etc r (Min olt" . model C ll - 200, Osaka. J ap:m) . T hree measure-
mellI's (*a scale ) were recorded pe r sicc by the o pera to r. who was IllJa wa re 
of the actual trC<l rnl c llt g ive n . T hese va lues we re ave ra ged fo r each site. 
Keratom ed secti o ll s (= 150 1.A.1Il ill thi ckness ) o f skill and /o r 4 111m pun ch 
bio psies w ere o b tOlin cd under \ IX! lidocaine anesthes ia fru lll each site. 
Kcrato lll cd spccinlc ll s w ere inul1cdia tcl y froz-en in li quid nitrogen and 
storcd at - 7 (J °C until used . Each punch biopsy was plnced in 10% 
l1 eu t ral - buffe rcd fo rl1wiill a lld processed fo r hCI11atoxylin alld eos in hi sto l-
ogy. All participants gave in fo rmed writte n co nscnt in a pro tocol ap proved 
b y the Uni ve rsity of Michiga n Medical Center Institu tio nal R eview Bo ard . 
RA 4-Hydroxylase Assay Microsomal fra ctio ns Were prepared as pre-
vio usly described (Du ell 1'1 al. 1992). The rate of I~A metabo lism was 
dete rmined by incuba ting 100 f.J.g o f epidermal microsolllal prote in in 0.0 I 
M phosphate bufte r (1'1-1 7.4) containing l.ll-lil- I'l...A and a NA I)I'I-I regener-
ating systcm . Salllples were incubated at 35 °C fo r 30 min . The reacti on w as 
termin ated b y add itio n of 100 f.J.1 o f l11 ethano l cooled to - 20°C. 
Extraction and Separation of Retinoids An HPLC syste l11 (1090 M ; 
H ew lett- Packard Co .. Palo Alto. C Al w ith a Sphe ri so rb O I)S- 1 co lu lTln (25 
111111 X 4 .6 mm). a diode arra y detecto r. and a chem wo rkstation was used 
to se parate and quall tir;t te rc rin o ids alld Ill e tabo li tes (dc tcc l"i o n lirni t. 'I ng). 
Kera tom e bio psies we re ground to po wder nnder liquid ni trogen w ith a 
morta r and pestl e. The powdered epidermis was transferred to tenBroeck 
ho rn ogenizer conta ining 10 vo lum es o f chlo ro lo rl11:m ethano l (2 :1 . vo l/vo l) 
w ith a trace amo unt o f r.l H1I-I'l...A and ho m ogenized w ith 10 strokes o f the 
pestl e. T he homogenate \ '''IS decanted in to I S-1Tl1 po lypro pylene tubes and 
vo rtexed (o r 5 min. Afte r centrifugation at 1 (JOO X g fo r I () min. the 
superna ta nt fractio n W:lS trans fe rred to a 15-ml po lypro pylene tube . T he 
pe ll e t w as re-ex tracted w ith an adeli tional 10 vo lumes o f chlo roform : 
ll1cthano l w ith vo rtcx ing fo r 5 Jnin. Afte r centri fugatio n. thc supc nwtant 
fraction was combined with th e initi al supe rn atan t fracti on . T he pellet was 
ex tracrcd with 5 vo lum es o f Ill ethano l:water pH 3 .2 (85 : 15. vo l/vo l) with 
vo rtcx in g fo r 5 Inin . After centrifugati o l1 , the supe rnatall t fracti o n was 
add ed to prev io us superll atant tractio ns. A sanlpl c o f th e conlbill cd supe r-
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natant fr actions was transferred to a 12 X 75 mm glass tube, placed in a 
wa te r bath, and evaporated under a stream o f nitrogen . Additional samples 
w ere added to the tube until the entire sample w as evaporated to dryness . 
T he contents o f the tube were resuspended in 200 f.J.I o f methanol with 0. 5 
m g bu tylated hydroxy to luene per 1111 of methanol and filtered through 
Millipore SJHV004 fi lters into HPLC vials. The sample w as evaporated to 
dryness . the ma te rial w as resuspended in 30 J.A.I of m ethanol, and 25 J.A.I o f the 
suspension was injec ted ontO the J-/PLC colul11n. M o bile phases used for 
gradient e lution of retinoids , the flow rate , and the toml time for separation 
were as previo usly described (Duell el ai , 1992) . EfHu ent fro l11 the HPLC 
co lul11n flo wed directl y into a sc in tilbtion counter (Flo- one Beta m odel 
295A. Packard Instrumen t Co.) to determine radioactivity in each peak. 
C alculatio n of the amount o f metabolite was based o n rhe specifi c activi l)· 
of added [3H]RA. 
Extraction and Quantitation of Liarozole In experimen ts to deter-
mine liarozole le vels in viable e pidermis, all liarozole-treated sites were 
tape- stripped to "gli stening" to remove stratum co rneUI11 befo re kcratom-
iug. Adequacy of stratUJ11 carn CUI11 rClnoval "vas COnfirI11Cd by Li·ozen 
section hi stology o f a 2 111m punch bio psy obtained fro m each tape-sn'ipped 
tes t site. Kerato ll1cd biopsy sp ec il11 en s ""ere inll11cdiatc i}' frozen ill liq uid 
nitrogen , and the froze n tissue was gro und with a mortar and pes tle to a fi ne 
powder. T he po wdered tissue was transferred to a ten.l3roeck hom ogenizer 
containin g 10 volulIles of 0. 0"1 M N aOH per g o f tissue and 200 ng of 
irtemazole as inte rnal standard and vo rtexed in termittentl y fo r ·1 (J min . After 
centrifugatio n at 2000 X g fo r 5 min . the supernatant fi·act io ns were 
removed and applied to Merck Ex trclur 3 columns. Afte r 5 min. liarozole 
and irtemazo le we re e lured fro l11 the co lumn with 4 1111 o f heptane: isoamyl 
alco ho l (9: 1, vol/vo l). T he e mu 'n t was evaporated to dryn ess under a 
streanl o f lI itrogen and the res idue was resuspellded ill ace tonitrile. "pplied 
to a re vers\! phase HPLC C ' H co lumn, and separated with a linear gnldienr. 
T he ini t ial cO l'l1positio n o f th e g racti c l1l \vas 51% so lvellt A laceto nitril c:O. 1 M 
NI-I .,Ac (1 :·1) I and 95% so lve n t U lacetonitril e:O. 1 M N H .,A c (6:4) \. and 
100% so lvent U was reached at 8 min . The !low rate was 0.7 ml pCI' min . and 
lhe run ,.vas tcnnil1atc d aft-c r 20 Jilin. IrtcTJI;1zo lc :Ind li a rozo1c w ere 
quallti tated wi t.h an in-Jine H ewlett-Packard I046A flu o rescence detector 
using 27R 11 111 as exc ita t io n WiJvc )c n g th ilnd 30 2 11111 as c rniss io n wavelength 
(de tection limit. 6 IIg). Standard so lu ti ons o f li arozo le alld irtelllazo le w\!rc 
used to calibrat.e the sys tem prio r to separatio n o f ex u'acted salllpies. 
Histology PUl1 ch bio psy spccinlc ns processed 'w ith hCl1'la toxy lin and 
eosin were read under li ght microscopy by o ue in ves ti gato r (KJ .K .) who 
w as 1Illa W'lre o f which lTeat lllCl1t g ruup each spec im e J1 represe llte d. Ep idcr-
nl al thi ckness w as In c aslIrcd fro lH th e epidcnl1al baselll c l1t Jll elllhrane to the 
bottonl of strat ll ill corn c um at fl vc inter- rete rid g-c si tes. ano th e di stances 
w ere avcr:l ged . 
Statis tical Analysis Com parisons o f m ean levels o r vari o lls par;lIl1c rcrs 
<l 111 o n g treated sites w e re m ade w ith e ithcr the paired t tC!'i t o r th e repeated 
l11 c asurcs an alysis o f variance. AlI P va ill es are two sided . SUnll1laq ' stati stics 
arc expressed as nl C'lns ~ SEM . Dilta anal ys is w as pcrto r1n cd with th e li se 
of the Michigan In teractive na ta Ana lys is Syste lll (MIDA S), a statistical 
software pac kagc de velo ped at. the Cellte r lo r Stati sti cal C OlISulta tio n and 
I.t..csea rc it ~Jt th e U niversity of Michi ga n . 
r~ESULTS 
Liarozole Inhibits RA-Induced Human Epidermal RA 
4 - Hydroxylase Activity To determin e whether li aroz ole can 
inhibit I~A 4 -h ydro x yla se . w e fir st indu ced the cytoc hrome P-450 
e n zym e in human skin ill ,,;"" b y RA c ream o cc lusive a'c atme nt for 
4 d. Mi c rosolll es d e ri ved fi 'o l1l th c l~-trcated sites w e rc th en 
assayed fo r transfo rma t io n of RA to 4-hydro x y R.A in th e absen ce 
of and with vary ing d oses of liaroz ol e . In cOlllpari son to eHll~ 
a lo n e (200 :!:: ·17 pg /lll in / I\lg lIli c rosollla l prote in), I ' HJI"0\ con- ' 
ta inin g liarozole demonstrated dose-de pendent reduction in 4 - 0H 
l'l...A fo rllla tion (Fig 1). In in c ubations conta ining 5 X l () - .I M 
liarozo le, close to 9 () 'Y., inhibition (p = 0.001 3) o f th e P-450-
m e diate d ac ti v ity was noted. 
Liarozole and RA Levels, and RA 4-Hydroxylase Activity i n 
Human Skin After 3')/0 Liarozole Application Havin g e stab-
li shc d ;11 II ;Iro that liarozole inhibits hUlllan e pide rmal RA 4-h ydrox-
ylase ac tivity , w e next in ve sti g ated pe rc utan eou s absorptio n of 
topi cal li a rozole and its e ffcc t o n ti ssu e R.A le vels. In stratum 
cornc ulll-frce v iable epid e rmis , li arozole conte nt was ·1. 3 ± OJ 
(= 4 /-LM) and 3.0 ± 0.7 (= 10 /-LM) /-Lg/g wet w e ig ht a fte r 1.8 and 
4 8 h o f o cclus ivc tre atment, respectiv e ly (Fig 2A). In 14 o f the 17 
vo lun teers, I"lA was n o t d ete c table (de tectio n limit = I n g ) in 
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Figure 1. Inhibition of RA-induced cytochrome P-450-mediatcd 
transformation of RA into 4-0H RA by liarozolc. COlldil'ioll s for ill 
vitro assay of th e rni croso ll1 a l fraction froln ItA-treated sites and analytical 
procedures arc detailed ill Mal erials tl lld Mcr hods. Va lu es 0 11 the x "x is refer 
to liarozole concelltrations. COlllparison o r I"HIR.A /lCW IS I·' HIR.A + 
li arozo lc gave the fo llow ing cO ll ccn tra ti o n-clcpcnd c nt pe rcent decreases 
and p va lu es: 5 X 10- " M (89'1.,: 0.00 13), 5 X 10- 5 M (6\1')'0 : 0.0(02), S X 
10- 6 M (52%: 0.(018). Data represent lIlea ll ::': SEM, n = 8. D, I.\ HIRA 
(1 X 10- (' M):., I " HJRA ( I X 10- (' M) + li arozole. 
vehicle-treated skin (trace levels in three subjects). E ighteen ho urs 
of liarozole treatment (19 ± 5 ng/g wet wt; = 63 nM) mark edl y 
increased epiderma l ItA levels (p < 0 .002; Fig 2B). Despite the 
grea te r le ve l o f lia rozo le measured at 48 h compared to '18 h. the 
epidermal RA le vel was o nly 6 ± 2 ng/g net weight (= 20 nM) (p = 
0.38 I'ers((s vehic le). 
Beca use RA is known to induce its own in activatio n, w e w ish ed 
to d e termine whether tbe reduc tion in ItA level fi 'o m I t3 to 48 h 
was assoc ia ted w ith concomitant indu c tion of RA -4-0Hase activ-
ity . Indeed, by 48 h of lia rozo le occlusion, RA 4- 0 H ase ac ti v ity 
increased 9-fold over that of vehicle treatment (p = 0.026: Fig 2C). 
Retinoid Response of Low-Dose RA and Retinol Is En-
hanced by Liarozole To determine whether inhibition of RA 
4-hydroxy lase by liarozo le can in crease the potcncy of low-dose 
retino ids in terms of clinica lly detectabl e paramcters , we utiLi zed a 
4-d patch test bioa ssay. We examined clinica l, hjsto logic , and 
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Figure 2. A) Liarozolc content in areas treated for 18 and 48 h widt 
3.0% liarozole followed by removal of surface liarozo]e by tape-
stripping of stratum corneum. Stri ppi llg tedlJ1ique alld extractio ll 
procedures arc detailed ill Mntnials (/ ,111 Melh"ds. Dal'a represent llle" l1 ::': 
SEM,11 = 7. *p < 0.007 ""1'.1'11..- vehicle; N .D., nOlldctectable. B) Liarozo le 
trcatlll cnt :-!lOI1 C tr ansie ntl y elevates ti ss li e itA level s. Data represellt 
mean ::': SEM, n = 17. ' p < O.O()2 I'C' S II"- vehicle; /V. O .. lIolldetectable. C) 
3% Liarozolc induces aftcr 48 h hUlllall epidermal R..A-4-hydroxy lasc 
acti vity . Condi t io ll s fo r iI/ ";fm <1ssa ys and separatio n of rnctabo litcs arc g iven 
in. Ma lerials alld Met hods. Data represent Ill eall ::': SEM, n = 8. *, P < 0.03. 
0 , vehicle; • . li arozole. 
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biochemi ca l respo n scs of nOI'mal human skin afte r 4 d of occl usive 
treatm c nt with liarozo le (3'1..) and/or low-dose retin oids (0. 00 1% 
retino ic acid , 0.025% retin o l) sepa rate ly and in combinatio n and 
compared them to both positi ve (0.0 25% RA) and n cga ti ve (vehi -
cle) contro ls. 
C lillical alld Hislologic R{'.ij10IlSI' Degree of redness in the treH tm en t 
sites as measured by chromi1mc ter is summarized in Fig 3. As 
expected, 0.025% KA indu ccd the m ost e rythema. Although 
0.00'] 'Yu RA and 3% liarozolc separate ly did not indu ce m o re 
e rythema than did vehicle, the two toge ther inc rca scd the eryth ema 
score to a le ve l simi lar to that of 0.025% .RA (Fig 3A). N o 
stati stica ll y signifi cant diffe ren ce in the epidermal thickness was 
obsel'vcd between 0.00 1 % R A, 3'1\, liarozo le, and vehi cle-treated 
sites (Fig 3B), but 0.00 1%, RA in combination with 3% liarozo le 
inc rea sed epide rmal thickness similar ly to 0.025% R A. \V ith low-
dose ROL (0.025%) , th e addition of liarozole did nor enhan ce th e 
e ryth ema respon se as co mpared to each agent alone or to rhe 
vehiclc (Fig 4A). Ep ide rmal thickness in the combin ation treatment 
site was signifi cantly greater, however, than that produced by eith er 
component alon e , approachj n g the thickness found in the 0.025% 
ItA treatment site (Fig 4B). 
RA 4-H)'drox )'las(' illdllclio(( Ii)' LOllI-Dose R l'lill oids Is Ellir allced IJ)' II/{, 
Addilioll oj Liaro:ole After 96 h of continuous occlusio n with 3% 
liarozole, RA 4-hydroxylase ac tivity was still slightl y (36-56%) 
indu ced compared to trea tment wirh ve hicle. Although a low dose 
ofRA (O .OOl (V,,) o r ROL (0.025%) separately increased hydro xylase 
activity (1 ()4'X, and 133%. respecdvcIy). the addition of3% li arozo lc 
furth e r stimulated activity in a synergistic fas hion (288% for RA + 
LZ. and 262% fOI' R OL and L Z). 
DISCUSS ION 
T his study dcm on strates that li arozole is an effective inhibi tor of 
human epidermal R A 4-hydroxylase activ ity and that this pharm a-
cologic property can be u sed to amplj fy human skin responses to 
retinoids. O ur ill " ilro data confirm the previous finding that a sing le 
topical dose ofR A applied to human skin u.nd er constant occlusion 
for 4 d m arkedly il1duces JtA 4-hydroxylase activi ty (Duell 1'1 ai, 
1992). A ltho ugh a forma l IC st> va luc detcrmination was n ot made. 
approximate ly 50% inhibiti o n of RA-4-hydroxy la 'c activity w as 
achieved by 5 J.LM li arozole. Under simil ar condi tions, 5 J.LM 
ketoconazole inhibited human epiderm al RA 4-hydroxylase activ-
ity by 68% (D ue ll 1'1 al. 1992). In ham ster live r microsome 
prepa rations, the two imidazoles wel'e eq uipotent in their ability to 
inhibit RA 4- 0 1-1ase activ ity (Van W auwe eI al. 1992). 
A ph armaco logica ll y active con centration of lia rozole (5 J.LM) 
determined i ll lI ilro was easily reach ed in v iable epide rmis within 
18 II after sin g le application of 3% liarozo le. In deed , at that timc. 
the marked increase in tissu e R A levels indicates au effecti ve 
blockade of endogenous ItA metabo lislll. The signjtic,111tIy e le-
vated RA level achieved early (18 h), h owever, was late r (48 h) lost 
durin g treatment despite a further ri se in tissue liarozo lc leve ls (= 9 
J.LM at 48 h). The accompan yin g indu ction ofRA 4-0Hase ac tiv ity 
atter 48 II of liarozole treatment impli es enhan ced meta bolism of 
RA as the cau se of R ..A level red uctio n . T he extent to w hich 
reduc tion o r inhibi tio n of RA bi osyn thes is, if any, by an unk nown 
feedba ck m echanism. rm1y con tribute to this redu ctio n in R.A levels 
was not addressed in this study. We have rece ntly demonstrated in 
hum an skin ill lIi IJo, howe ver, that topical app li cation ofRA fo r 24 h 
can signifi ca ntl y inc rease ce llul ar re tin o l bindin g prote in (CRBP) 
mRNA (= 5-fo ld) an d protein (= 3-fo ld) levcIs (Fisher CI nl, 1995). 
Bccause ho lo-CRBP (all-Imlls ROL - bound C RBP) is a substratc 
fo r b o th re tiny l este r fo rmatio n (lecithin : retin o l acy l tra nsferase) 
and re tin o l oxidation (re tin o l de hydrogenase) (Napo li, 1993; O ng 
('I ai, 1994), in tbe case of lia rozo le-inducedRA accumulati on. 
C RBP may have been induced, limitin g RA synthesis by pro m oting 
re tino l esterifica tion (i.e .. storage) . 
T h e 30-h lag-timc between the incrcase in tissu e RA levels and 
the indu c tio n of RA 4-0H ase activi ty a fter lia rozole applicatio n is 
con sistent w ith the time course of the cnzym e induction fo llowin g 
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F ig ure 3. Liarozole induces both erythema (A) and epidermal hyperplasia (B) responses of human skin to low dose retinoic acid in a 4-d 
patch test. T he )llllnal! s kill hioassa)1 cO lldi tion s and procedures for erythema all d cp idcrllIal thickness nl C;:ls urCIIH!ll ts arc described ill l\ /aleria/s rllld A/cllwns. 
Data represent mean :<:: SEM. n = 7 . • , P < 0.05 ""rsll s ItA O.025'Y". 
more th,1I1 1 fi but less than 24 h afte r 0 .1 'Yo, I~A appli cation to human 
skin ;11 II ;"" (Du e ll cl ai , 1996). Similar activities were sustained fo r 
UfJ [0 4 d of I~ treatment. T he kinetics of coordinate ly regul ated 
induction of I~ 4-0J-lase in resfJonse to an in creased ItA level 
fi'o m liarozole-media ted enzyme inhibi t ion w ill largely determine 
the magnitude and dura tion of increased I~A leve ls in the tissue. In 
hum an skin, the magnitude of induction in RA 4-0Hase activi ty 
con'cla tes w ith the dose ofR A apfJli ed (Duell, Kang, :1I1d Voorhees, 
unpublished observatio ns). T he la ck of cl ini cal (Fig 3) and histo-
logic (Fig 4) resfJonses in human skin to 3% li arozole alo ne in the 
4-d fJatch test indi ca tes tha t beca use of the in du cible comfJensatory 
mechani sm ( I~ 4-01-lase), t he net in crease in RA was not large 
e nou gh to trigger th e cascade of events that result in m eas urable 
clwn ges in the two parameters. T he dynami c lI ature of the contin-
uous inte rpla y betwee n li arozole- in duced e levation of I~ and the 
resul tan t induction of R.A 4-0I-lase . w hi ch in turn arc subject to 
liarozole inhibi tion. is reflected in the chan g" in R-A 4-0J-lase 
activity fi'ol11 4~ h (""' 9-fold, Fig 2C) to 96 h (less than 2-fo ld . Fig 
5) of li arozole treatment. 
Our sfJeculation that an exogenous so urce of I~. provided in 
con ce rt with liarozole . would a lte r th e kinetics of the ItA-regu la-
to ry system toward a more protracted RA-sufflcient state is sup-
fJorted by ou r data . As reported before, U.I)()1 % R-A and 0 .025% 
ROL indi vidll<lll y were not associated with e rythema o r signifi cant 
ep iderm al hyperfJl as ia in compari son w ith vehi c le (G riffi ths el Il l , 
1993; Kang el ai, 1995). In combinatio n with li :Hozole, however . 
these low doses of R.A and R-OL were similar to lU)25% RA in 
indu cin g epidermal hYfJerplasia. Ind eed, co mpared to each compo-



























4- 0 l-la se activity, indi catin g in crea sed I~ activity in th e tissue. 
This increase, howeve r, was markedl y less than that with 0.025% 
I~A. Although dail y appli catio n of 0.025')1" ItA to hum an skin is 
conside red safe, with no detecta ble in crease in pla sma R-A levels 
(13uchan CI fll, 1994). una voida bl e system ic I~ absorption re mains 
a concern . T hel·efore. expos ing skin to lesser amounts of I~ may 
be sa fer. III this context, top ica l usc of U.001 % I~ and 0.025% 
ROL lower the possibi li ty of systemic I~ abso rpti o n comfJared to 
0.025% I~. 
Altho ugh I~ and R OL. w he n co-administe red with liarozole. 
were similar in abi li ty to enhan ce the histologic response of human 
skin , on ly ItA, and lIo t R.O L, indu ced erythema. T his disparate 
respo nse . however, is consistent with our curren t und erstanding of 
fJ hannaco logic actio n and m etaboli sm of re tin o ids in human skin. 
We have recently de m onstrated in normal skin that topi cal R OL as 
well as R-A can indu ce efJid e rmal h YfJe rfJlasia and mL~NA expres-
sio n of I~-respon sive genes su ch as ce llul ar R.A bind in g protein-II 
and CRBP-I (K:lI1g cl Il l. 1995). These responses were observed 
without signifi ca nt cl inica l e rythe ma o r detectable increase in I~ 
levels when tested with up to '1.6% R-OL. T hi s ;11 11;110 o bserva tion, 
sUfJported by ;11 11;11'0 hUl11 an keratinocyte data (Kurlandsky ('I Ill, 
1994), stron gly suggests that R.O L-induced skin cfl'Ccts arc l11edi-
ated by tightl y regu lated conversio n to I~. which functions as 
li gand to ac tiva te nu clear I~ recepto rs. l3ec:l use the R OL oxida-
tio n to RA needs to occur at specific ce llular locatio ns w here the 
appropriate enzymati c m achin e ry (reti no l/ retinal dehydrogellases) 
is present, inhibition of l~ ina ctivation by liarozole wou ld raise the 
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F i g ure 4. Liarozole amplifies epidermal hyperplasia (B) response of human skin to low dose retinol without causing erythema (A) in a 4-d 
patch test. COllditio ll s for the bioassay :llld procedures fo r erythema alld epidermal th ickll ess measuremen ts arc described in iHlI/eria/s "lid Me f/",r/s . Data 
represent mea ll :<:: SEM . n = 7 for A and H fo r U. ' . p < 0.05 lIerS llS ltA 0.025%. t.. P < 1!.lIS "S (RO L + li arozo le). 
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Figure 5. Liarozole augments RA 4-0Hase ac tivity of human e pidermis treated for 4 d with low dose RA (A) and retinol (B). Microsom al 
fractions fro IT) sites trented 'w ith indicated agents were used ill i ll 11;lf,) incubatio ns. Assay con d it io ns an d an alytica l proced ures arc d escribed ill ,\1nltTin/s miff 
)\t1e.tlwds. COTllpa ri soTl s of va ri o liS tn.~' l t1l1 CI1t sites IIcr S fiS vc hiclc-trc'ltcd sites gave the follo\ving in creases in 4-0 H ItA fO flllali o n and p values: for rccinoic ncid 
(n = 11 ) (II) 3':;', li arozo le alo ne (36':;',; 0.028 t); 0.O()1 % ItA (104%; 0.0(04); 3% li arozole + (1.1)0 '1 % RA (288%; 0.0(17) : 0.025% RA (559%; O.()()(ll). For 
retino l (n = II ) (8) 3% lia rozolc alonc (56'X,: 0.(45 1) : 0.025% n .Ol ( 113'%: 0.(0 14): 3% liarozok + 0.025% R.Ol (262%: 0.0(29): 0.025% RA (1277%: 
0.000). Data re present llI ean ::': SEM. 
O ur d ata indica te that liarozole is an eR-ective inhibitor of human 
epiderma l R"A 4-0Hase activity. We have demonstrated ill IIi"" in 
humans that . after li arozole inhibi tion of RA 4- 0 Hase. tissue R.A 
level is elevated and a co mpensatory m echani sm (RA 4- 0Hase 
induction) is engaged. Furthermore, we establish the pharmaco-
logic prin ciple that RA 4-0J-lase inhibi tio n can enhance the tissue 
RA level provided by low doses of R.A and ROL in a sho rt-te rm 
bi oassay. Whethe r thi s enhancem e nt ca n also be maintain ed in 
clinically re leva nt situations (i.e .. un occlud ed dai ly use) mu st be 
investigated . If fOll nd to be practica l and eWective, this ph:lI"In:l co-
logic m 'lIli p ul atio n may lead to a sa fe r way of de li ve ring [crino ids to 
human skin. 
J¥e (ltnul, Rob;" Gn rd,, ('/" ""d 5"z(/I/ RehiJi"c Ji'r Ilt eir "-"P('/'f;SC ill nppl)';".~ 11tC' 
COIHPOJIllr/S, r(,1I1t",il1.~ stra lll lll (O n'CIIIII I /li lli /fI}U'-s l r il'l'illg I lI !t (,1I required, alld 
kcrn(ol1/;"g 4 Ihe ,ren/1'I1 arC'ns. I v,· "Is" 11111,," T .. d A. Ha",;II, '" .fi". stal;sl;wl 
mlnl)'sis) J "ditlt Vn n 13l1rell .I,,,. her Icc/1IIicnl ('s}Jerf isf', La ll ra I 'a" Coo,. for lite 
ill llsrraf iolls, flllri /Jail' )"('""siml./i1/' sccfc/nrinl (/.\'5 ; ... ((11/( (' . 5f'''01l /(n".<: is II I't'(ilJic' llI 
of lite Dcn" o(olog), F"'IIIdal;o". Gln.I·/l O"n"nl"I ".~)' CI;";,-,,I Career 0..",,/,,1''' '''''' 
Awnrd. T his I I 'I "'}.' /I1I1S ,\' II/Ilmned ;11 !,(lrI hy th e Babcock Elldcn l'II"' IIr. 
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